secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2026-08-14T20:07:25+00:00
Accession:  0001193125-26-352208
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LeonaBio Q2 2026 net loss $19.0M; cash $51.1M; ELAINE-3 enrollment on track
---------------------------------------------------------------------------

- Net loss $19.0M ($0.80/sh) vs $7.0M ($1.78/sh) in Q2 2025; R&D spend up to $12.9M from $3.7M.
- Cash, equivalents and investments $51.1M at June 30, 2026, down from $88.3M at Dec 31, 2025; ops cash burn $37.9M in quarter.
- ELAINE-3 Phase 3 trial enrolled 495 patients; enrollment completion expected Q4 2026, topline data 2H 2027.
- Up to $146M potential from cash-exercisable warrants from Dec 2025 financing to support development.
- Board additions: Fred Callori, Natalie Holles, Peter Silverman effective May 5, 2026; John Fluke retired May 4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000119312526352208/0001193125-26-352208-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000119312526352208/lona-20260814.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-352208

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer